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Abstract: Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome present in 
patients with liver disease that includes impaired intellectual function. To develop therapeutic 
treatments to restore cognitive function, it is important to understand the molecular mechanisms 
that impair cognitive function in HE. This review summarizes data showing that: (a) cogni-
tive function and learning are impaired in patients with liver disease and in animal models of 
chronic liver failure or hyperammonemia; (b) the glutamate–NO–cGMP pathway modulates 
some forms of learning; and (c) the function of this pathway is impaired in brain in vivo in rats 
with chronic hyperammonemia or liver failure and from patients who died from HE. Learning 
ability of hyperammonemic rats was restored by increasing cGMP by: (1) continuous intra-
cerebral administration of zaprinast, an inhibitor of the cGMP-degrading phosphodiesterase; 
(2) chronic oral administration of sildenaﬁ  l, an inhibitor of the phosphodiesterase that crosses 
the blood–brain barrier; and (3) continuous intracerebral administration of cGMP. The data 
summarized indicate that impairment of learning ability in rats with chronic liver failure or 
hyperammonemia is due to impairment of the glutamate–NO–cGMP pathway. Moreover, 
increasing extracellular cGMP by pharmacological means may be a new therapeutic approach 
to improve cognitive function in patients with HE.
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Hepatic encephalopathy
Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome present in 
patients with chronic or acute liver disease. HE covers a wide range of neuropsychi-
atric disturbances ranging from minimal changes in personality or altered circadian 
rhythms (sleep–waking cycle) to alterations in the intellectual function, personality, 
conscience, and neuromuscular coordination. HE is usually reversible, but in the worse 
cases can lead to coma and death.
The neurological alterations in HE are the result of a previous failure of 
liver function. Liver failure leads to impaired detoxiﬁ  cation of ammonia and 
other toxic substances that can reach the brain and alter its function. Many 
studies have been carried out to identify factors responsible for the neurological 
alterations in HE. Clinical experience and basic research indicate that ammonia 
is the main factor responsible for HE. Ammonia is a product of degradation of 
proteins and other nitrogenated compounds but at high concentrations ammonia 
is toxic, leading to alteration of cerebral function which can lead to coma and 
death.Neuropsychiatric Disease and Treatment 2006:2(1) 54
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Hyperammonemia is therefore considered the main 
factor contributing to the neurological alterations found in 
HE both in acute and chronic liver disease (Ferenci et al 
1984; Lockwood et al 1991; Felipo and Butterworth 2002; 
Wang and Saab 2003). Classical clinical treatment of HE 
is mainly directed to reducing ammonia concentration by 
lowering ammonia production by the intestinal bacteria 
and by reducing ammonia transport from intestine to the 
blood ﬂ  ow by acidiﬁ  cation of the intestinal lumen. Overt 
HE is usually elicited by a precipitating factor (high protein 
ingestion, gastrointestinal constipation, bleeding, diuretics) 
usually associated with increased ammonia levels. Cogni-
tive, motor (extrapiramidal and cerebellar signs), and sleep 
alterations (impairment of sleep–wake cycle) are commonly 
observed in patients with HE and their intensities vary with 
the grade of HE. Patients with HE show alterations in cogni-
tion, consciousness, attention, memory, and learning.
Motor alterations include increase in muscular tone, 
reduced speed of rapid alternating movement, ataxia, an 
increase in deep tendon reﬂ  exes, abnormal movements such 
as tremors, and, particularly, asterixis. Also hypomimia, 
dysarthria, bradykinesia, and hypokinesia could be detected 
on careful neurological examination.
Alterations in the regulation of biological rhythms such as 
sleep, appetite, melatonin production, and in sexuality are com-
mon in patients with liver disease (Iguchi et al 1982; Steindl 
et al 1995; Garﬁ  nkel and Zisapel 1996; Cordoba et al 1998).
Patients with liver cirrhosis with normal neurological 
and mental status examination may present minimal forms 
of HE, showing intellectual function impairment that can-
not be detected through general clinical examination but 
can be unveiled using specific neuropsychological and 
neurophysiologic examination (Ferenci et al 2002; Amodio 
et al 2004).
This neurophysiological examination includes the use of 
EEG as a tool to monitor the severity of HE and the changes 
due to treatment. Alterations of EEG patterns in cirrhosis are 
roughly related to the alterations of mental state (Parsons-
Smith et al 1957). Both qualitative and semi-quantitative 
scales for grading of the EEG alterations due to HE have 
been proposed (eg, Parsons-Smith et al 1957; Amodio, 
Marchetti, et al 1999). Spectral analysis of EEG tracing to 
quantify and classify the alterations due to HE is also being 
used (eg, Van der Rijt et al 1992; Amodio et al 1996, 2001). 
This technique provides a quantitative estimation of the 
EEG based on the relative power of frequency bands and 
the mean dominant frequency. These EEG techniques may 
detect minimal HE.
The prevalence of minimal EH ranges from 30% to 84% 
depending on the kind and number of tests used and the popu-
lation (etiology and severity of the liver disease) investigated. 
Cirrhotic patients with minimal HE are “clinically normal” 
but present cognitive alterations which can be unveiled by a 
detailed analysis of the patients’ history and by neurological 
and neuropsychiatric assessement of consciousness and of 
sensory, cognitive, and motor function.
Even minimal HE has been associated with reduced qual-
ity of life and ability to work and to drive (Schomerus et al 
1981; Srivastava et al 1994; Groeneweg et al 1998; Marche-
sini et al 2001; Schomerus and Hamster 2001). Moreover, 
patients suffering minimal HE have increased probability of 
suffering later overt HE (Amodio, Del Piccolo, et al 1999; 
Hartmann et al 2000; Romero-Gomez et al 2001).
Intellectual function is impaired 
in HE
Early manifestations of intellectual dysfunction in HE 
include psychomotor slowing and impaired ability to per-
form tasks that require sustained attention (McCrea et al 
1996; Schomerus and Hamster 1998; Amodio, Del Piccolo, 
et al 1999). As encephalopathy worsens, impairment in 
speech and inability to copy simple drawings (eg, a star) 
appear. In grade II HE, temporal and spatial disorientation 
and reduced vigilance state or delirium have been observed. 
Grade IV HE is characterized by the appearance of stupor 
and coma.
Patients with minimal HE show impaired ability to 
perform memory tasks, mainly because of deﬁ  cits in atten-
tion and visual perception (Tarter et al 1987; Weissenborn 
et al 2003). These patients also perform worse than healthy 
controls in motor function, visual perception, visual 
orientation, visuo-constructive abilities, and attention 
(Rehnström et al 1977; Rikkers et al 1978; Gilberstadt 
et al 1980; Tarter et al 1984). Performance in recognition 
and free recall tasks is also impaired in these patients 
(Weissenborn et al 2003).
The psychomotor slowing present in patients with 
minimal HE is due to cognitive rather than motor deﬁ  cits, 
as indicated by the fact that delays in choice reaction times 
are more strongly impaired than the delays in simple reaction 
times (Rikkers et al 1978; Schomerus et al 1981).
Sustained attention is also impaired in cirrhotic patients 
even when memory, language, constructive, or pure motor 
alterations are absent (McCrea et al 1996; Weissenborn et al 
2001, 2003). Patients with minimal HE have a tendency to 
be easily distracted.Neuropsychiatric Disease and Treatment 2006:2(1) 55
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Animal models of chronic HE show 
neurological alterations similar 
to those in patients with HE
Hyperammonemia is considered the main contributor to the 
pathogenesis of HE, but the mechanisms by which liver fail-
ure and hyperammonemia lead to the associated neurological 
alterations are not well understood.
To try to study these mechanisms a few animal models 
are being used. The most usual model to study the neuro-
logical alterations in HE is the rat with chronic liver failure 
induced surgically by portacaval anastomosis. In this model 
a surgical shunt is constructed between the portal and the 
inferior cava veins. Thus blood does not pass through the 
liver, and ammonia and other substances are not properly 
detoxiﬁ  ed, can reach the brain, and lead to neurological 
alterations.
This animal model reproduces some of the neurologi-
cal alterations found in patients with HE. Rats with por-
tacaval anastomosis show impaired circadian rhythms of 
locomotor activity and food intake (Zee et al 1991; Steindl 
et al 1996; Cordoba et al 1997; Lozeva et al 2000, 2002; 
Lopez et al 2002).
Reduced motor activity is also observed in rats with por-
tacaval anastomosis, which is similar to the motor slowing, 
hypokinesia and bradykinesia present in patients with HE 
(Bengtsson et al 1986, 1989; Martin et al 1986; Apelqvist 
et al 1998, 1999; Lozeva et al 2000). Reduced motor activity 
has been also observed in rats with bile-duct ligation, another 
model of HE (Chan et al 2004).
Learning ability is reduced in animal 
models of HE
Cognitive function is also altered in animal models of chronic 
liver disease. When normal rats are moved from the cage where 
they usually live and are placed in a novel cage, they start to 
explore it, resulting in increased motor activity. If rats are placed 
in the same cage during consecutive days, the exploratory 
behaviour decreases since the animal remembers the novel cage 
and the interest for it lowers. In rats with portacaval anastomosis 
this long-term habituation is impaired. This has been interpreted 
as consequence of a possibly impaired learning–memory capac-
ity in these rats (Apelqvist et al 1999).
A more direct demonstration of impairment of learning 
ability in rats with portacaval anastomosis has been reported 
recently by Erceg et al (2005a), who showed that the ability 
of these rats to learn a conditional discrimination task in a 
Y maze is lower than that of control rats.
Rats with biliar obstruction (another model of HE) show 
impaired learning ability in a working memory test consisting 
of an object recognition task, ie, show decreased ability to 
discriminate between novel objects and previously known 
objects (Garcia-Moreno et al 2005). Working memory is also 
altered in patients with HE (Elithorn et al 1975).
As mentioned above, hyperammonemia is considered the 
main factor contributing to the pathogenesis of HE. However, 
liver failure induces, in addition to hyperammonemia, other 
alterations (such as decreased muscle mass, altered metabolism 
of other compounds). To discern the contribution of hyperam-
monemia to the neurological alterations in HE, we developed 
an animal model of chronic hyperammonemia without liver 
failure:rats fed an ammonium-containing diet (Azorin et al 
1989). These rats present a level of hyperammonemia similar 
to that of patients with liver cirrhosis or of rats with portacaval 
anastomosis, but do not present other alterations associated 
with liver failure and may be considered therefore as a model 
of “pure” hyperammonemia.
Learning of a conditional discrimination task in a Y maze 
is impaired in these rats with chronic hyperammonemia 
without liver failure (Aguilar et al 2000) as well as in rats 
with chronic liver failure due to portacaval anastomosis 
(Erceg et al 2005a).
In patients with liver disease, increase in hyperammonemia 
worsens (and reduction of hyperammonemia improves) neu-
ropsychiatric and neurological scores in patients with HE.
In summary the above studies show that animal models 
of HE reproduce some of the neurological alterations found 
in patients with HE and are therefore adequate to study the 
molecular mechanisms by which liver failure leads to these 
neurological alterations. Moreover, the above studies also 
show that chronic hyperammonemia is responsible for at least 
some of the cognitive alterations observed in HE.
Molecular mechanisms modulating 
learning
The studies summarized above show that cognitive function 
and learning ability are impaired both in patients with liver 
disease and HE (either minimal, non clinical HE) and in 
animal models of hyperammonemia and liver failure.
To try to develop appropriate therapeutic treatments 
to restore cognitive function it is important to understand 
the molecular mechanisms that modulate learning ability 
as well as the mechanisms by which these processes are 
altered in hyperammonemia and HE. The molecular bases 
for different types of learning are not well known. It has 
been proposed that N-methyl-D-aspartic acid (NMDA) Neuropsychiatric Disease and Treatment 2006:2(1) 56
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receptors play a crucial role in some types of learning. 
However, the molecular mechanisms by which activation 
of NMDA receptors modulate learning remain unclear. 
Activation of NMDA receptors leads to increased calcium 
in the post-synaptic neuron. Calcium binds to calmodulin 
and activates neuronal nitric oxide synthase, increasing 
nitric oxide (NO), which activates soluble guanylate 
cyclase, increasing guanosine 3',5'-(cyclic)phosphate 
(cGMP). Part of this cGMP is released to the extracellular 
space (Figure 1). Several reports suggest that activation of 
this glutamate–NO–cGMP pathway is involved in some 
forms of learning (Danysz et al 1995; Chen et al 1997; 
Meyer et al 1998).
NMDA receptors modulate some 
kinds of learning
There is a large amount of evidence that activation of NMDA 
receptors is involved in some forms of learning. We sum-
marize below some of the data available.
The most frequent experimental approach to analyze the 
role of NMDA receptors in learning processes is the study 
of the effects of blocking NMDA receptors with selective 
antagonists on the ability of experimental animals to learn 
different kinds of tasks.
This kind of study has shown that both competitive and 
noncompetitive antagonists of NMDA receptors alter learn-
ing and memory processes in a Y-maze (Parada-Turska and 
Turski 1990; Maurice et al 1994). Administration of NMDA 
receptor antagonists also alters learning of different kinds of 
tasks: passive avoidance (Riekkinen et al 1996; Smith et al 
1997), active avoidance (Delay 1996; Redolat et al 1998), 
spacial tasks (Murray and Ridley 1997), classical conditional 
tasks (Xu 1997), and 14-unit T-maze (Patel et al 1998) and 
spatial learning in the Morris Water Maze (Morris et al 1986; 
Packard and Teacher 1997).
In addition to the studies using antagonists, there are 
genetic studies that support a role of NMDA receptors in cer-
tain types of learning (McHugh et al 1996; Tsien et al 1996; 
Huerta et al 2000; Rampon and Tsien 2000). Mice that do not 
express the NMDA receptor subunit NR2A have decreased 
spatial learning ability (Sakimura et al 1995). On the other 
hand, overexpression of the NR2B subunit in transgenic mice 
increases NMDA receptor activation and improves learning 
and memory (Tang et al 1999).
It is therefore clear that NMDA receptors play a role in 
learning. The subsequent steps by which activation of NMDA 
receptors mediates learning processes are not so clear. Some 
reports suggest that activation of the glutamate–NO–cGMP 
pathway associated to NMDA receptors is involved in some 
forms of learning.
Role of NO, soluble guanylate 
cyclase, and cGMP in learning
Activation of NMDA receptors leads to activation of NO 
synthase and to increased formation of NO. NO seems 
to mediate at least part of the role of NMDA receptors in 
learning. This is supported by studies showing that inhibition 
of NO synthase reduces learning of some spatial tasks: 
14-unit T-maze (Ingram, Spangler, Kametani, et al 1998; 
Ingram, Spangler, Meyer, et al 1998) or radial maze (Zou 
et al 1998). It also impairs memory consolidation in objects 
recognition tasks (Prickaerts et al 1997) and learning of 
passive avoidance tasks (Myslivecek 1997).
The role of NO in learning may be mediated by its 
activation of soluble guanylate cyclase and the increase in 
cGMP. Some reports indicate that soluble guanylate cyclase 
and cGMP are important in learning and memory. Bernabeu 
et al showed that, in rats, passive avoidance learning 
was associated with a time-dependent, learning-speciﬁ  c 
increase in cGMP (Bernabeu et al 1996) and in cGMP-
dependent protein kinase activity in the hippocampus 
(Bernabeu et al 1997).
The same group also showed that administration of a 
membrane permeable analog of cGMP facilitated memory 
consolidation (Bernabeu et al 1996), while bilateral intrahip-
pocampal administration of an inhibitor of soluble guanylate 
cyclase caused full amnesia for inhibitory avoidance learning 
when given immediately after training (Bernabeu et al 1997). 
These results support a role for soluble guanylate cyclase and 
cGMP in learning and memory.
Smith et al (2000) tested later whether activation of soluble 
guanylate cyclase and increased cGMP formation in the brain 
would improve learning in cognitively impaired animals. They 
showed that a nitrate ester that activates soluble guanylate 
cyclase improved learning in scopolamine-pretreated animals 
in a time- and dose-dependent manner. The authors suggested 
that stimulation of cerebral soluble guanylate cyclase might 
be an effective strategy to improve learning and memory 
performance in individuals in whom cognitive abilities are 
impaired.
Yamada et al (1996) also showed that blocking NMDA 
receptors with dizocilpine or inhibiting NO synthase 
impaired spatial working memory in mice and suggested 
that the reduction in NO–cGMP production in the brain 
may be responsible for dizocilpine-induced impairment of 
learning.Neuropsychiatric Disease and Treatment 2006:2(1) 57
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On the other hand, administration of zaprinast, a selective 
inhibitor of the phosphodiestease that degrades cGMP, 
improves early stages of object recognition memory consoli-
dation (Prickaerts et al 1997). Microinjection of 8 Br-cGMP, 
a membrane permeable analog of cGMP, into the dorsal hip-
pocampus also improves performance in object recognition 
tasks (Prickaerts et al 2002).
These data indicate that the increase in cGMP produced 
by guanylate cyclase in response to NO has a crucial role in 
some types of learning.
Chronic hyperammonemia with 
or without liver failure impairs 
glutamate–NO–cGMP pathway in 
rat cerebellum in vivo
Chronic moderate hyperammonemia in rats, similar to 
that present in patients with liver cirrhosis, impairs the 
glutamate–NO–cGMP pathway in the cerebellum in vivo, 
as shown by brain microdialysis in freely moving rats by 
Hermenegildo et al (1998). Microdialysis probes were 
inserted in the cerebellum of control or hyperammonemic 
rats without liver failure. Administration of NMDA through 
the microdialysis probe activates the glutamate–NO–cGMP 
pathway and increases cGMP formation. Part of the cGMP 
formed is released to the extracellular ﬂ  uid (Figure 1), and 
the increase in extracellular cGMP is a good measure of 
the function of the glutamate–NO–cGMP pathway in the 
cerebellum in vivo. Hermenegildo et al (1998) showed that 
the NMDA-induced increase in extracellular cGMP in the 
cerebellum was signiﬁ  cantly lower in hyperammonemic rats 
than in control rats, indicating that chronic hyperammonemia 
impairs the glutamate–NO–cGMP pathway in the rat 
cerebellum in vivo (Figure 2a).
To assess whether the impairment occurs at the level 
of activation of soluble guanylate cyclase by NO, a 
NO-generating agent, S-nitroso-d,l-penicillamine (SNAP), 
was administered through the microdialysis probe to activate 
directly guanylate cyclase. The increase in extracellular 
cGMP induced by SNAP was also signiﬁ  cantly reduced 
in hyperammonemic rats (Figure 2b). This indicates that 
chronic moderate hyperammonemia impairs activation 
of soluble guanylate cyclase by NO in the cerebellum in 
vivo, resulting in impairment of the glutamate–NO–cGMP 
pathway.
Chronic liver failure, induced by portacaval anastomosis, 
also impairs the glutamate–NO–cGMP pathway in the 
cerebellum in vivo, as shown by brain microdialysis in freely 
moving rats by Monfort et al (2001) (Figure 2c). NMDA-
induced increase in extracellular cGMP in the cerebellum was 
signiﬁ  cantly lower in rats with portacaval anastomosis than 
in control rats, indicating that chronic liver failure impairs 
NMDA RECEPTOR 
CM
Glutamate
Ca2+
Fe2+
nNOS
NO cGMP GTP 
2+ Ca cGMP
sGC
Figure 1 The glutamate–NO–cGMP pathway.   Activation of ionotropic (mainly NMDA) glutamate receptors leads to increased intracellular calcium (Ca2+) which, after 
binding to calmodulin (CM), activates neuronal nitric oxide synthase (nNOS) leading to increased production of NO, which in turn activates soluble guanylate cyclase (sGC), 
resulting in increased formation of cyclic 3´-5´-guanosine monophosphate (cGMP) from guanosine-5´-triphosphate (GTP). Part of the cGMP formed is released to the 
extracellular space.Neuropsychiatric Disease and Treatment 2006:2(1) 58
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of chronic liver failure and of chronic hyperammonemia. 
Moreover, the step of the pathway mainly affected is the 
activation of soluble guanylate cyclase by NO.
Modulation of soluble guanylate 
cyclase by NO is altered in cerebral 
cortex and cerebellum of patients 
who died from HE
To assess whether activation of soluble guanylate cyclase by 
NO is also altered in cirrhotic patients with HE, we measured 
activation of soluble guanylate cyclase by the NO-generat-
ing agent SNAP in homogenates of the frontal cortex or 
cerebellum from controls and from cirrhotic patients who 
died from hepatic coma.
The activation of guanylate cyclase by the NO-generating 
agent SNAP was signiﬁ  cantly lower (63%) in the cerebellum 
from cirrhotic patients than in controls. In contrast to the 
cerebellum results, activation of guanylate cyclase by NO 
was higher (about 200% of controls) in the frontal cortex 
from patients than in controls (Corbalán et al 2002).
The above results show that activation of soluble gua-
nylate cyclase by NO is altered both in the cerebral cortex 
and cerebellum of patients who died from hepatic coma. 
However, the effects are opposite in these areas, showing 
increased activation in the cortex and decreased activation 
in the cerebellum (Corbalán et al 2002).
The mechanism by which the same pathological situation 
(liver cirrhosis) can lead to opposite effects in the cerebellum 
and cerebral cortex is not yet clear. The results obtained sug-
gest that some intrinsic factor in the neurons, different in each 
cerebral area, may lead to opposite responses to ammonia of 
the modulation of guanylate cyclase by NO.
Differential modulation of other processes in the cerebel-
lum and cortex has been previously reported. For example, 
activation of NMDA receptor induces choline release in corti-
cal neurons but not in cerebellar neurons in culture and this 
release has been related to excitotoxic cell death (Gasull et al 
2000). Also, the regulatory subunits of adenosine 3',5'-cyclic 
monophosphate (cAMP)-dependent protein kinases are 
differentially expressed in cortical and cerebellar neurons 
leading to a differential ability of these neurons to transmit 
cAMP signals to the nucleus (Paolillo et al 1999). Also the 
role of neuronal NO in the coupling between cerebral blood 
ﬂ  ow and local neuronal activity is different in these cerebral 
areas. NO is important in neurovascular coupling in the cer-
ebellum but its role in the neocortex is less important, and 
it seems that in this area other neurotransmitters are more 
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Figure 2 Hyperammonemia impairs the function of the glutamate–NO–cGMP 
pathway in the cerebellum in vivo by reducing NO-induced activation of soluble 
guanylate cyclase. The effects of NMDA or SNAP on extracellular cGMP in the 
cerebellum of control, hyperammonemic rats without liver failure (2a and 2b) 
and with chronic liver failure (2c) were analyzed by in vivo microdialysis in freely 
moving rats. NMDA (0.1 and 0.3 mM) or SNAP (0.3 mM) was administered in 
the perfusion stream for 20 minutes at the times indicated by the horizontal bars. 
Perfusion was carried out at 3 μL/minute, samples were collected every 20 minutes, 
and cGMP was determined. Data are presented as a percentage of basal values. 
Data were analysed using two-way ANOVA.
a intragroup comparison values signiﬁ  cantly different from baseline (p   0.05 by 
Kruskal-Wallis test with post hoc Dunnett´s test;  * values signiﬁ  cantly different 
from control (p   0.05). 
Figure 2a and 2b from: Hermenegildo C, Montoliu C, Llansola M, et al. 1998. 
Chronic hyperammonemia impairs glutamate-nitric oxide-cyclic GMP pathway 
in cerebellar neurons in culture and in the rat in vivo. Eur J Neurosci, 10:3201–9; 
Figure 2c from: Monfort P, Corbalán R, Martínez L, et al. 2001. Altered content and 
modulation of soluble guanylate cyclase in the cerebellum of rats with portacaval 
anastomosis. Neuroscience, 104:1119–25.
the function of the glutamate–NO–cGMP pathway in the rat 
cerebellum in vivo.
These results indicate that the function of the glutamate–
NO–cGMP is altered in brain in vivo in animal models Neuropsychiatric Disease and Treatment 2006:2(1) 59
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relevant in neurovascular coupling (Hayashi et al 2002). 
It is not surprising therefore that liver cirrhosis may affect 
differentially the modulation of soluble guanylate cyclase in 
the cerebellum and cortex.
Animal models of chronic 
hyperammonemia and of liver failure 
reproduce faithfully alterations 
in modulation of guanylate cyclase 
by NO found in brain 
of cirrhotic patients
To study the molecular mechanisms responsible for the 
alterations of modulation of guanylate cyclase by NO in the 
cerebral cortex and cerebellum of patients with liver cir-
rhosis and to test possible therapeutic treatments to reverse 
this alteration, it is important to have animal models that 
faithfully reproduce the effects found in human patients. 
We assessed whether animal models of hyperammonemia 
with or without liver failure reproduce the alterations in the 
modulation of guanylate cyclase by NO.
Rats with chronic liver failure due to portacaval anas-
tomosis faithfully reproduce the increased activation of 
soluble guanylate cyclase by NO in the cerebral cortex and 
the reduced activation in the cerebellum (Monfort et al 2001; 
Corbalán et al 2002).
Rats with bile duct ligation plus hyperammonemia 
also reproduce the alterations in the modulation of soluble 
guanylate cyclase both in cerebral cortex and in the cerebellum 
(Rodrigo et al 2005). The reduced activation in the cerebellum 
is also reproduced in rats with chronic hyperammonemia 
without liver failure (Rodrigo et al 2005).
These results show that animal models reproduce faith-
fully the alterations in the modulation of guanylate cyclase 
by NO found in brain of patients who died from HE due to 
liver cirrhosis. Other forms of HE such as Reye’s syndrome 
or Wilson’s disease are much less frequent and have been 
less studied, and it is not yet possible by now to compare 
the neurobiological alterations in these situations with those 
of cirrhotic patients or to assess the validity of the animal 
models to study these disorders.
These animal models are therefore adequate to:
1) study the molecular mechanisms by which liver 
failure alters the function of the glutamate–NO–cGMP 
pathway;
2)  assess the functional consequences of this alteration and 
its contribution to the neurological alterations in HE, for 
example in learning ability;
3) test possible therapeutic treatments to normalize the 
function of the glutamate–NO–cGMP pathway and to 
normalize the altered neurological functions, for example 
learning ability.
Pharmacological manipulation 
of extracellular cGMP concentration 
in brain restores learning ability 
in rats with chronic liver failure 
or chronic hyperammonemia
The data summarized above show that:
a)  cognitive function and learning ability are impaired 
in patients with liver disease and in animal models of 
chronic liver failure or of chronic hyperammonemia;
b) the glutamate–NO–cGMP pathway modulates some 
forms of learning;
c)  the function of the glutamate–NO–cGMP pathway is 
impaired in brain in vivo in animal models of chronic 
hyperammonemia and of chronic liver failure and also in 
autopsied brain from patients who died from HE
We hypothesized that:
a)  the alterations in the function of the glutamate–NO–
cGMP pathway and the decrease in extracellular cGMP 
in the brain in hyperammonemia and liver disease may 
be responsible for the impairment in learning ability and 
intellectual function, and that
b) pharmacological modulation of extracellular cGMP 
concentration may restore learning ability in hyperam-
monemia and HE.
To assess this possibility we tried to reverse the impairment 
in learning ability of hyperammonemic rats by increasing 
cGMP. We increased extracellular cGMP by using three 
different treatments:
1) continuous intracerebral administration of zaprinast, 
an inhibitor of the phosphodiesterase that degrades 
cGMP;
2)  chronic oral administration of sildenaﬁ  l, an inhibitor of 
the phosphodiesterase that crosses the blood–brain bar-
rier, and
3)  continuous intracerebral administration of cGMP.
Continuous intracerebral zaprinast 
increases extracellular cGMP 
and restores learning ability 
in hyperammonemic rats
We tested whether increasing cerebral cGMP by inhibiting 
its degradation is able to restore learning ability in Neuropsychiatric Disease and Treatment 2006:2(1) 60
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hyperammonemic rats. We administered intracerebrally 
zaprinast, an inhibitor of the phosphodiesterase that 
degrades cGMP, to control or hyperammonemic rats, 
continuously for 28 days, by using osmotic minipumps. 
Extracellular cGMP was significantly reduced in 
hyperammonemic rats and treatment with zaprinast 
increased extracellular cGMP to the same level present 
in control rats.
We carried out tests of conditional discrimination 
learning with control and hyperammonemic rats treated 
or not with zaprinast. Learning ability was signiﬁ  cantly 
reduced in hyperammonemic rats. Continuous intrace-
rebral administration of zaprinast to hyperammonemic 
rats completely restored the learning ability of these rats 
(Erceg et al 2005b). This indicates that increasing cGMP 
by inhibiting its degradation restores learning ability in 
hyperammonemic rats.
The changes in extracellular cGMP are parallel to changes 
in learning ability, supporting a role for cGMP levels in 
learning ability.
Oral sildenaﬁ  l normalizes function 
of glutamate–NO–cGMP pathway and 
extracellular cGMP and restores learning 
ability in rats with chronic liver failure 
or with hyperammonemia without liver 
failure
As shown above, zaprinast is effective in restoring learning 
ability in hyperammonemic rats, but it does not cross the 
blood–brain barrier and is therefore not suitable for clinical 
treatment of patients.
We therefore studied whether oral administration of 
sildenaﬁ  l, an inhibitor of the phosphodiesterase that degrades 
cGMP and crosses the blood–brain barrier, restores learn-
ing ability in rats with chronic liver failure or with chronic 
hyperammonemia without liver failure.
Chronic oral treatment with sildenaﬁ  l normalizes the 
function of the glutamate–NO–cGMP pathway and extra-
cellular cGMP in rats with portacaval anastomosis and also 
restored the ability of rats with portacaval anastomosis to 
learn the Y maze conditional discrimination task (Erceg 
et al 2005a).
Hyperammonemia is one of the main factors contributing to 
the neurological alterations in HE. To assess the role of hyper-
ammonemia in the alterations in learning ability, extracellular 
cGMP, and function of the glutamate–NO–cGMP pathway 
observed in rats with portacaval anastomosis, we carried out 
experiments similar to those reported above using rats with 
chronic moderate hyperammonemia without liver failure.
Chronic hyperammonemia signiﬁ  cantly reduced the ability 
of rats to learn the conditional discrimination task. Treatment 
with sildenaﬁ  l normalized the function of the glutamate–
NO–cGMP pathway and extracellular cGMP in hyperammo-
nemic rats without liver failure and restored their ability to learn 
the conditional discrimination task (Erceg et al 2005a).
Continuous intracerebral administration 
of cGMP restores learning ability 
in hyperammonemic rats
To further conﬁ  rm that changes in extracellular cGMP are 
responsible for the changes in learning ability, we tested 
whether increasing only extracellular cGMP without affecting 
intracellular cGMP is also able to restore learning ability in 
hyperammonemic rats. To do this we administered cGMP intra-
cerebrally to control or hyperammonemic rats, continuously 
for 28 days, by using osmotic minipumps. cGMP is not able to 
cross the cellular membrane and therefore increases cGMP only 
in the extracellular ﬂ  uid. We carried out tests of conditional 
discrimination learning with control and hyperammonemic rats 
treated or not with cGMP. Continuous intracerebral administra-
tion of cGMP to hyperammonemic rats completely restored 
the learning ability of hyperammonemic rats.
The results summarized above clearly point out a role 
for extracellular cGMP concentration in the ability of rats 
to learn the Y maze task. Changes in extracellular cGMP are 
parallel to changes in learning ability, supporting a correla-
tion between cGMP levels and learning ability.
The possible mechanisms by which extracellular cGMP 
would modulate learning are not yet clear. Only a few 
reports suggest some physiological role for extracellular 
cGMP as a neuroprotector against excitotoxicity (Montoliu 
et al 1999) and as a modulator of sodium uptake in kidney 
(Sasaki et al 2004). However, the mechanisms involved 
remain unclear.
Conclusion
In conclusion, the above data indicate that the impairment 
of learning ability in hyperammonemic rats with or without 
chronic liver failure is due to impairment of the glutamate–
NO–cGMP pathway. As the function of this pathway is 
also altered in the brain of patients with liver cirrhosis, this 
alteration should also contribute to the cognitive impairment 
in these patients.
Moreover, increasing extracellular cGMP by pharmaco-
logical means may be a new therapeutic approach to improve Neuropsychiatric Disease and Treatment 2006:2(1) 61
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learning and memory performance in individuals in whom 
cognitive abilities are impaired for different reasons, for 
example, in patients with evident HE and also in patients with 
minimal (subclinical) HE who present reduced performance 
in psychometric tests.
The modulation of extracellular cGMP can be 
achieved by different means: modulation of its synthe-
sis by soluble or particulate guanylate cyclase or of its 
degradation by phosphodiesterases. There are already 
pharmacological tools to apply these treatments to patients. 
Several companies are selling inhibitors of phosphodies-
terases that may increase extracellular cGMP and are also 
investigating new molecules that may modulate cGMP 
levels. The inhibitors of cGMP-degrading phosphodies-
terase (mainly of phosphodiesterase 5) used in the animal 
studies described above are currently being used for the 
clinical treatment of erectile dysfunction and of pulmonary 
hypertension. In fact, sildenaﬁ  l is the active component 
of Viagra®.
However, in the case of cirrhotic patients, caution 
must be taken considering the possible deleterious 
increase in the existing vasodilatation in liver disease by 
sildenaﬁ  l (Tzathas et al 2002). It has also been reported 
that in patients with ascites and cirrhosis, inhibition of 
phosphodiesterase 5 leads to increased plasma levels of 
the rennin–angiotensin–aldosterone system (Thiesson et al 
2005). Therefore additional studies seem to be required to 
ﬁ  nd some safe procedure to increase extracellular cGMP in 
the brain without inducing deleterious effects in peripheral 
tissues. Pharmacological manipulation of cGMP in the brain 
by safe procedures may be a useful treatment to restore 
cognitive and intellectual functions in patients with overt 
or minimal HE.
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